Xenon Pharmaceuticals Inc. 2025-2026 Proxy Voting Records

1. To approve, on an advisory basis, the compensation of the Corporation's named executive officers;

Combines 10 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay").”): 82,156,320 for, 4,769,025 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 85% for, 5% against (90% of the company cast a for/against vote).

The 306 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

Showing the 25 largest of 306 asset managers. See all 306 in the interactive database.

2. To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;

Combines 9 wordings of this item as funds reported it.

99.9% fund support · no official result

The 300 asset managers below cast 99.9% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

Showing the 25 largest of 300 asset managers. See all 300 in the interactive database.

3. To approve the Corporation's 2026 Equity Incentive Plan;

Combines 3 wordings of this item as funds reported it.

80% fund support · no official result

The 90 asset managers below cast 80% of the shares they voted on this item FOR (28,050,226 for, 7,101,763 against).

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

4. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn Svoronos

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Dawn Svoronos”): 82,475,281 for, 4,517,221 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 85% for, 5% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 98% of the shares they voted on this item FOR (34,217,715 for, 697,649 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

5. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth Garofalo

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Elizabeth Garofalo”): 84,808,573 for, 2,183,929 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 88% for, 2% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 99.4% of the shares they voted on this item FOR (34,726,341 for, 189,023 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

6. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary Patou

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Gary Patou”): 86,114,511 for, 877,991 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 89% for, 1.0% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 99.6% of the shares they voted on this item FOR (34,788,338 for, 127,026 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

7. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian Cannon

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Gillian Cannon”): 84,844,120 for, 2,148,382 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 88% for, 2% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 99.4% of the shares they voted on this item FOR (34,726,341 for, 189,023 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

8. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian Mortimer

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Ian Mortimer”): 86,524,582 for, 467,920 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 90% for, 0.5% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 99.9% of the shares they voted on this item FOR (34,888,487 for, 26,877 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

9. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin Gover

Combines 4 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Justin Gover”): 86,290,281 for, 702,221 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 89% for, 0.8% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 99.9% of the shares they voted on this item FOR (34,888,487 for, 26,877 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

10. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick Machado

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Patrick Machado”): 86,603,916 for, 388,586 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 90% for, 0.5% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 99.9% of the shares they voted on this item FOR (34,888,487 for, 26,877 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

11. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven Gannon

Combines 4 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Steven Gannon”): 86,149,107 for, 843,395 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 89% for, 0.9% against (90% of the company cast a for/against vote).

The 88 asset managers below cast 99.9% of the shares they voted on this item FOR (34,888,487 for, 26,877 against).

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

12. To appoint PricewaterhouseCoopers LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation;

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Proposal Five – Appointment of Auditor.”): 90,371,967 for, 27,668 withheld, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 94% for, 0.1% withheld (94% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (34,887,810 for, 0 against).

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

13. To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation; and

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

Xenon Pharmaceuticals Inc.’s own tally for this item (“Proposal Six – Remuneration of Auditor.”): 90,370,029 for, 2,369 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,624,123 outstanding shares: 94% for, 0.1% against (94% of the company cast a for/against vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (34,887,810 for, 0 against).

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

14. Advisory Vote on Say on Pay Frequency

100% fund support · no official result

The 5 asset managers below cast 100% of the shares they voted on this item FOR (677 for, 0 against).

15. Approve Omnibus Stock Plan

93% fund support · no official result

The 3 asset managers below cast 93% of the shares they voted on this item FOR (109,609 for, 7,771 against).